Cero Analysis: $1M Raised

Focus on clinical trials and funding through public offerings and private placements.

Cero Therapeutics operates in the biotechnology sector, focusing on innovative tumor cell clearance through its CER technology platform. Its main competitors include:

1. TCR CURE Biopharma: This company develops cancer immunotherapies and is a private entity founded in 2017. It is headquartered in Los Angeles and has around 20 employees. Its focus on T cell receptor (TCR) therapies differentiates it in the immunotherapy landscape.

2. Celularity: A public biotechnology company founded in 2016, Celularity specializes in allogeneic cells and tissues derived from the postpartum placenta. With over 1,900 employees, it is significantly larger than Cero and has a broader operational scale, which may provide advantages in research and development.

3. Quentis Therapeutics: Founded in 2016, this private company focuses on immunotherapies that enhance the immune system's ability to combat cancer by targeting the endoplasmic reticulum stress response. It has a smaller workforce of 6 employees and has faced a workforce reduction, which may impact its operational capabilities.

4. Tmunity Therapeutics: Established in 2015, Tmunity is dedicated to next-generation T cell immunotherapy for severe diseases. It is also a private company with 10 employees and has experienced a decrease in staff, which could affect its growth potential.

5. Eureka Therapeutics: This venture capital-backed company is based in Emeryville, CA, and focuses on T cell therapies for cancer. Its financial backing may provide it with a competitive edge in research and development.

6. SIRPant Immunotherapeutics: Another competitor in the immunotherapy space, focusing on engineered T cell therapies.

7. PDS Biotechnology: This company is involved in developing immunotherapies for cancer treatment, competing directly with Cero in the tumor clearance market.

8. Turnstone Biologics: Focused on developing oncolytic virus therapies, it represents a different approach to cancer treatment compared to Cero's technology.

9. A2 Bio: This company is also involved in the biotechnology sector, focusing on cancer therapies.

Notable differences among these competitors include their specific therapeutic approaches, funding levels, and the types of cancer they target, which can influence their market strategies and potential advantages.

Cero Therapeutics primarily focuses on the biotechnology industry, specifically in the area of tumor cell clearance through their innovative CER technology platform.